Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunotherapy in Parkinson’s disease: Current status and future directions
Diptaman Chatterjee, Jeffrey H. Kordower
Neurobiology of Disease (2019) Vol. 132, pp. 104587-104587
Open Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

Neurodegeneration and Inflammation—An Interesting Interplay in Parkinson’s Disease
Chrysoula Marogianni, Maria Sokratous, Efthimios Dardiotis, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 22, pp. 8421-8421
Open Access | Times Cited: 266
Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial
D. Volc, Werner Poewe, Alexandra Kutzelnigg, et al.
The Lancet Neurology (2020) Vol. 19, Iss. 7, pp. 591-600
Closed Access | Times Cited: 105
Emerging Therapeutic Strategies for Parkinson’s Disease and Future Prospects: A 2021 Update
Noha Gouda, Ahmed Elkamhawy, Jungsook Cho
Biomedicines (2022) Vol. 10, Iss. 2, pp. 371-371
Open Access | Times Cited: 57
Lysosomal exocytosis releases pathogenic α-synuclein species from neurons in synucleinopathy models
Ying Xue Xie, Nima Naseri, Jasmine A. Fels, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 55
LSTM-CNN: An efficient diagnostic network for Parkinson's disease utilizing dynamic handwriting analysis
Xuechao Wang, Junqing Huang, Marianna Chatzakou, et al.
Computer Methods and Programs in Biomedicine (2024) Vol. 247, pp. 108066-108066
Open Access | Times Cited: 11
Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disorders
Anne Messer, David C. Butler
Neurobiology of Disease (2019) Vol. 134, pp. 104619-104619
Open Access | Times Cited: 72
Targeting α‐synuclein aggregation and its role in mitochondrial dysfunction in Parkinson's disease
Md. Ezazul Haque, Mahbuba Akther, Shofiul Azam, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 1, pp. 23-45
Open Access | Times Cited: 51
MOG autoantibodies trigger a tightly-controlled FcR and BTK-driven microglia proliferative response
Kathryn Pellerin, Stephen Rubino, Jeremy C. Burns, et al.
Brain (2021) Vol. 144, Iss. 8, pp. 2361-2374
Open Access | Times Cited: 48
Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study
Werner Poewe, D. Volc, Klaus Seppi, et al.
Journal of Parkinson s Disease (2021) Vol. 11, Iss. 3, pp. 1079-1089
Open Access | Times Cited: 47
Are Therapies That Target α-Synuclein Effective at Halting Parkinson’s Disease Progression? A Systematic Review
A. Rodger, Maryam N. ALNasser, Wayne G. Carter
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 11022-11022
Open Access | Times Cited: 20
A Comprehensive Review on Neuroimmunology: Insights from Multiple Sclerosis to Future Therapeutic Developments
Lucian Eva, Horia Pleș, Razvan-Adrian Covache-Busuioc, et al.
Biomedicines (2023) Vol. 11, Iss. 9, pp. 2489-2489
Open Access | Times Cited: 17
Immunotherapy: An emerging treatment option for neurodegenerative diseases
Abhiyanta Mukherjee, Soumojit Biswas, Ipsita Roy
Drug Discovery Today (2024) Vol. 29, Iss. 5, pp. 103974-103974
Closed Access | Times Cited: 6
A Transcriptome Analysis of mRNAs and Long Non-Coding RNAs in Patients with Parkinson’s Disease
Michele Salemi, Giuseppe Lanza, Maria P. Mogavero, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1535-1535
Open Access | Times Cited: 23
Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model
Lin Li, Lingyu Zhang, Qianqian Jin, et al.
Neural Regeneration Research (2021) Vol. 16, Iss. 8, pp. 1660-1660
Open Access | Times Cited: 32
Neurodegeneration and inflammation crosstalk: Therapeutic targets and perspectives
Wael Mohamed, Jaya Kumar, Badrah S. Alghamdi, et al.
IBRO Neuroscience Reports (2022) Vol. 14, pp. 95-110
Open Access | Times Cited: 22
The major histocompatibility complex participates in Parkinson’s disease
Rou Gu, Jianyu Pan, Maher Un Nisa Awan, et al.
Pharmacological Research (2024) Vol. 203, pp. 107168-107168
Open Access | Times Cited: 4
Neurodegenerative disorders, metabolic icebergs, and mitohormesis
Matthew Phillips, Martin Picard
Translational Neurodegeneration (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 4
Disease-Modifying Therapies in Parkinson’s Disease
Margherita Fabbri, Jean‐Christophe Corvol, Olivier Rascol
Neurologic Clinics (2025) Vol. 43, Iss. 2, pp. 319-340
Closed Access
Approaches to Disease Modification for Parkinson’s Disease: Clinical Trials and Lessons Learned
Albert Y. Hung, Michael A. Schwarzschild
Neurotherapeutics (2020) Vol. 17, Iss. 4, pp. 1393-1405
Open Access | Times Cited: 29
Grabody B, an IGF1 receptor-based shuttle, mediates efficient delivery of biologics across the blood-brain barrier
Jung-Won Shin, Sungwon An, Dongin Kim, et al.
Cell Reports Methods (2022) Vol. 2, Iss. 11, pp. 100338-100338
Open Access | Times Cited: 18
Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?
Victoria Sidoroff, Pam Bower, Nadia Stefanova, et al.
Journal of Parkinson s Disease (2022) Vol. 12, Iss. 5, pp. 1369-1387
Open Access | Times Cited: 17
Role of Exosomes in Parkinson’s and Alzheimer’s Diseases
Himanshu Sharma, Siddhant Jai Tyagi, Phool Chandra, et al.
(2024), pp. 147-182
Closed Access | Times Cited: 3
Targeting α-synuclein aggregation with immunotherapy: a promising therapeutic approach for Parkinson’s disease
Gabriela Henrı́quez, Mahesh Narayan
Exploration of Neuroprotective Therapy (2023), pp. 207-234
Open Access | Times Cited: 8
Peri‐arterial pathways for clearance of α‐Synuclein and tau from the brain: Implications for the pathogenesis of dementias and for immunotherapy
Jacqui Nimmo, David A. Johnston, Jean‐Cosme Dodart, et al.
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 22
Peptide-Based Vaccines for Neurodegenerative Diseases: Recent Endeavors and Future Perspectives
Vyronia Vassilakopoulou, Chrysoula‐Evangelia Karachaliou, Alexandra Evangelou, et al.
Vaccines (2021) Vol. 9, Iss. 11, pp. 1278-1278
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top